ethyl 3-(t-butoxy)benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(t-butoxy)benzoate
• 英文别名: 3-tert-butoxy-benzoic acid ethyl ester；ethyl 3-tert-butyloxybenzoate；Ethyl 3-(tert-Butoxy)benzoate；ethyl 3-[(2-methylpropan-2-yl)oxy]benzoate
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: ZHMDHTVEPSNMLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(t-butoxy)benzoate 在 lithium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以92%的产率得到3-(叔丁氧基)苯羧酸
  参考文献：
  名称：

  Inhibition of Protein Kinase C-Driven Nuclear Factor-κB Activation: Synthesis, Structure−Activity Relationship, and Pharmacological Profiling of Pathway Specific Benzimidazole Probe Molecules

  摘要：

  A unique series of biologically active chemical probes that selectively inhibit NF-kappa B activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-kappa B activation.

  DOI：

  10.1021/jm1000248
• 作为产物：
  描述：

  3-羟基苯甲酸乙酯 、 异丁烯 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 以12.91 g (95%)的产率得到ethyl 3-(t-butoxy)benzoate
  参考文献：
  名称：

  Inhibitors of prenyl-protein transferase

  摘要：

  本发明涉及抑制异戊二烯-蛋白转移酶和致癌基因蛋白Ras的肽类模拟大环化合物。该发明还涉及含有本发明化合物的化疗组合物以及用于抑制异戊二烯-蛋白转移酶和致癌基因蛋白Ras的方法。

  公开号：

  US20020099007A1

文献信息

• Aminoethanol derivatives
  申请人：——

  公开号：US20040127574A1

  公开（公告）日：2004-07-01

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula 1 wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR″ is an optionally protected hydroxyl group, R is an acyl group, R′ is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药物剂，可用作降低血脂等方面的药物。本发明涉及一种由式1表示的化合物，其中Ar1是一个带有取代基的芳香环基团，Ar2是一个带有取代基的芳香环基团，OR″是一个可选保护的羟基，R是一个酰基，R′是一个氢原子或一个可选带有取代基的碳氢基团，或其盐，以及含有式(I)的化合物或其盐或前药的药物组合物。
• AMINOETHANOL DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1362846A1

  公开（公告）日：2003-11-19

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药剂，可用作降血脂药等。本发明涉及一种由式表示的化合物 其中 Ar1 是可选具有取代基的芳香环基，Ar2 是可选具有取代基的芳香环基，OR''是可选保护的羟基，R 是酰基，R'是氢原子或可选具有取代基的烃基，或其盐，以及含有式（I）化合物或其盐或其原药的药物组合物。
• US6566385B2
  申请人：——

  公开号：US6566385B2

  公开（公告）日：2003-05-20
• US6982348B2
  申请人：——

  公开号：US6982348B2

  公开（公告）日：2006-01-03
• [EN] INHIBITORS OF PRENYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE LA TRANSFERASE DE PROTEINE PRENYLE
  申请人：MERCK & CO INC

  公开号：WO2001051127A1

  公开（公告）日：2001-07-19

  The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.